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Abstract
Background: Cardiovascular diseases and other non-communicable diseases are major causes of morbidity and
mortality, responsible for 38 million deaths in 2012, 75 % occurring in low- and middle-income countries. Most of
these countries are facing a period of epidemiological transition, being confronted with an increased burden of
non-communicable diseases, which challenge health systems mainly designed to deal with infectious diseases. With
the adoption of the World Health Organization “Global Action Plan for the Prevention and Control of non-communicable
diseases, 2013–2020”, the national dimension of risk factors for non-communicable diseases must be reported on a
regular basis. Angola has no national surveillance system for non-communicable diseases, and periodic population-based
studies can help to overcome this lack of information. CardioBengo will collect information on risk factors, awareness rates
and prevalence of symptoms relevant to cardiovascular diseases, to assist decision makers in the implementation of
prevention and treatment policies and programs.
Methods: CardioBengo is designed as a research structure that comprises a cross-sectional component, providing
baseline information and the assembling of a cohort to follow-up the dynamics of cardiovascular diseases risk factors in
the catchment area of the Dande Health and Demographic Surveillance System of the Health Research Centre of Angola,
in Bengo Province, Angola. The World Health Organization STEPwise approach to surveillance questionnaires and
procedures will be used to collect information on a representative sex-age stratified sample, aged between 15 and
64 years old.
Discussion: CardioBengo will recruit the first population cohort in Angola designed to evaluate cardiovascular
diseases risk factors. Using the structures in place of the Dande Health and Demographic Surveillance System
and a reliable methodology that generates comparable results with other regions and countries, this study will
constitute a useful tool for the surveillance of cardiovascular diseases. Like all longitudinal studies, a strong
concern exists regarding dropouts, but strategies like regular visits to selected participants and a strong
community involvement are in place to minimize these occurrences.
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Background
Cardiovascular diseases (CVDs) are a leading cause of
death. In 2012 they were responsible for 17.5 million deaths
worldwide, and along with other non-communicable dis-
eases (NCDs) such as cancers, chronic respiratory diseases
and diabetes they constitute by far the major causes of
death that year. Around 75 % (28 million) of those deaths
happened in low- and middle-income (LMI) countries. Of
the 16 million of deaths caused by NCDs before the age of
70, 82 % took place in those countries [1].
CVDs and other NCDs share common risk factors
such as obesity, hypertension, hyperglycaemia or hyper-
cholesterolemia, smoking, physical inactivity, unhealthy
diets or alcohol [1, 2]. NCDs behavioural risk factors are
commonly associated with life styles whose conse-
quences usually manifest at older ages in high-income
countries. However, in the LMI countries NCDs are
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rising faster and affecting younger people, therefore
presenting earlier those consequences of adverse health
and economic outcomes [3, 4].
The growing burden of NCDs with their associated
premature mortality, are a major concern for health
systems decision-makers, especially in developing coun-
tries, were NCDs growth outpaced the reduction in
communicable diseases by 33 % between 1990 and
2010 [3]. The “Global Action Plan for the Prevention
and Control of NCDs, 2013–2020” adopted by all mem-
ber states of the World Health Organization (WHO)
defined nine voluntary global targets to be achieved by
2025, one being a 25 % reduction from 2010 levels in
NCD related preventable deaths (referred to as the
25x25 target) [5]. All signatories have committed to
report national levels of NCD risk factors on a regular
basis, reinforcing the key recommendations of the 2011
United Nations high-level meeting on NCDs which
included the strengthening of surveillance of NCD [6],
that allows a global and integrated mechanism to sup-
port the implementation of prevention and treatment
policies and programs.
The WHO STEPwise approach to Surveillance (STEPS)
was designed in 2007 to provide core data on the estab-
lished risk factors for the major NCDs based on standard-
ized questions and protocols that enable appropriate
comparisons across surveys. It uses a modular technique,
which allows to fit the specific needs and the available
resources for each setting [7].
STEPS was used in 36 African countries, between
2003 and 2013 [8], but not in Angola where four stud-
ies conducted between 2008 and 2014 provided the
available information on CVDs risk factors using other
methodologies: a survey in 667 adult students of
Health Sciences in Lubango, south of the country [9];
a study conducted in 615 active employees of a public
university in Luanda, the capital of Angola [10]; a
survey with 421 subjects from a rural community near
Luanda [11]; and a community-based survey with 1464
participants conducted by the Health Research Centre of
Angola (CISA) in the catchment area of the Dande
Health and Demographic Surveillance System (Dande-
HDSS) [12].
Using the Dande-HDSS structure for data collection
and management setting, we designed a new study,
named CardioBengo, to address the surveillance of the
major CVD risk factors with special emphasis on the
agreed selected NCD risk factors: tobacco use, harmful
alcohol use, salt intake, obesity, raised blood pressure,
raised blood glucose and diabetes and physical inactivity
but also covering the additional targets that focus on
treating people at high risk of heart attack and stroke
and on the availability of drugs to treat NCDs. Accord-
ingly, the study aimed to:
 Quantify the prevalence, awareness, treatment and
control of hypertension, hyperglycaemia and
hypercholesterolemia and their socio-demographic
and behavioural determinants, as a baseline for
future assessments;
 Describe tobacco, alcohol consumption, physical
activity and diet patterns;
 To run follow-up assessments every 3 years, to
monitor and understand trends in risk factors and
outcomes frequency.
Methods
Study design and setting
CardioBengo is a research to be conducted in the catch-
ment area of the Dande-HDSS, located in the Dande
Municipality, Bengo Province, 60 km north of Luanda, the
capital of Angola. Dande-HDSS monitors the structure,
dynamics and geographical distribution of a population of
60,075 people (53.5 % adults) that spreads across an area
of 4700 km2 with 70 hamlets across three communes
(Caxito, Mabubas and Úcua) [13]. This HDSS constitutes
the base for the identification of a representative popula-
tion sample to be invited to participate in the cohort
providing a baseline assessment and a longitudinal follow-
up evaluation planned at every 3 years, taking the same
approach used at baseline.
Sample size estimation and sampling
The sample size is calculated assuming a simple random
sample, based on the 23 % prevalence of hypertension
found for this population in a study conducted in 2011
[12], and anticipating a response rate of 70 %. The sam-
ple size estimates were generated for males and females
in five age groups between 15 and 64 years old, resulting
in a total of 3515 individuals. A random list will be
drawn from the Dande-HDSS population database.
Inclusion and exclusion criteria
The inclusion criteria are: i) living in the Dande-HDSS
study area at the time of the field work, ii) willingness
to participate in this study, and iii) age between 15 and
64 years. The exclusion criteria are: i) subjects with
missing anthropometric or blood pressure values and
ii) pregnant women; because their biochemical and
anthropometric parameters would vary from the non-
pregnant physiology they will be excluded from the
baseline analysis.
Pilot study
A pilot study was conducted to test data collection
instruments, procedures and to improve the training of
field workers. Adjustments in the language used in the
questionnaires were made, and the field logistics op-
timized to a model of five testing protocol stations,
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namely i) registry and socio-demographic data, ii) point
of care clinical tests, iii) anthropometric measures and
food habits, iv) blood pressure measurement and drug
treatment history and v) electrocardiogram, for the field
work facilities. The median time for each participant to
pass through all five stations was calculated in 2 h,
reaching to the conclusion that a maximum of 25 partic-
ipants in an 8 h day’s work is possible. All field workers
and health professionals selected to collaborate in the
study were involved on the pilot study and their skills
tested and improved, if necessary.
Enrolment of participants
One day before the arrival of the team that will implement
all the procedures related with the protocol, a field worker
visits the hamlets in order to prepare the necessary arrange-
ments for the field work, namely engaging with the local
authorities, involving them in the process of selection of an
adequate location to install the study facilities and in the
door-to-door contact of the prior selected participants, in
order to sensitize them to the objectives of the study and to
schedule their participation for the next days.
Selected individuals will be consider unreachable after
2 failed attempts of contact in their household at differ-
ent hours in weekdays, and a refusal will be recorded
when the contacted person explicitly says that he or she
doesn’t want to participate.
Each participant is expected to spend up to two hours
to complete the study tasks, receiving a small lunch at
the end, in order to compensate the fasting period previ-
ous to the exams. After the exams all participants will
receive a card summarizing their clinical and anthropo-
metric results and those with abnormal levels of blood
pressure, glucose, cholesterol or other clinical alteration
will be referred to the General Hospital of Bengo for a
follow-up evaluation with a medical doctor.
Study procedures
All procedures will be conducted by trained interviewers
from the Dande-HDSS and certified health professionals
(nurses, laboratory technicians and cardiopneumo-
graphic technician) able to communicate in Portuguese
(official language) and in the local languages. The proto-
col for data collection is based on the WHO STEPS
manual version 3.0 [7], translated to Portuguese, pre-
tested and piloted as referred above. All core items are
included and some of the expanded items adapted to the
specific context.
Demographic and social characteristics
Information on age, sex, marital status, current occupa-
tion, completed years of school frequency and household
income will be obtained using a questionnaire following
the STEPS manual [7].
Behavioural measurements
Information on smoking, namely current smoking status
and number of cigarettes smoked, will be collected as
described in the STEPS manual [7]. Additionally, a vali-
dated Portuguese version of the Fagerström test [14], is
used to assess smoking dependency. Alcohol intake, the
daily consumption of fruit, vegetables and oil or fat, will
be measured according STEPS manual [7]. The optional
module for dietary salt is also included in the question-
naire [7]. Physical activity and sedentary behaviour will
be assessed using all core and expanded items of the
STEPS manual [7].
Medication history
Following the STEPS guidelines [7], the history of eachindi-
vidual regarding hypertension, hyperglycaemia and hyper-
cholesterolemia, is obtained through questions evaluating
previous measurements of high blood pressure, glycaemia
and blood cholesterol. When any of these items are identi-
fied as positive, the participants will be asked about history
of recommendations or degree of awareness of such condi-
tions transmitted by a health professional. Any individual
will be considered under treatment if he/she indicates the
use of specific drug therapy and considered controlled if
he/she presents a normal measurement under a specific
drug therapy.
Female reproductive history
Data will be collected on menarche, reproductive history
(number of pregnancies and outcomes), pregnancy induced
hypertension, menopause and contraception methods used.
Clinical and anthropometric assessments
Physical exams will be performed with individuals wear-
ing light clothing, with no footwear and after an over-
night fast. For all participants, fasting conditions (more
then eight hours without eating) will be recorded. Waist
and hip circumferences will be measured to the nearest
0.1 cm using circumference tape SECA 203 (SECA
United Kingdom, Birmingham, UK). Body weight will be
measured to the nearest 0.1 kg using a digital scale
SECA 803 (SECA United Kingdom, Birmingham, UK).
Height will be measured to the nearest 0.1 cm in the
standing position using a portable stadiometer SECA
213 (SECA United Kingdom, Birmingham, UK). Body
mass index and waist to hip ratio will be calculated and
categorized according WHO guidelines [15, 16]. Blood
pressure will be measured using the automatic sphygmo-
manometer OMRON M6 Comfort (OMRON Healthcare
Europe B.V., Hoofddorp, The Netherlands), as recom-
mended [17]. Each participant will rest for 15 min before
measurements: seated, at the right arm, with an appro-
priate cuff size and 3 readings done at 3 min intervals.
An electrocardiogram and rhythm strip will be recorded
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from all participants using a 12-channel electrocardio-
graph AsCARD Mr.Grey V 201 (ASPEL, Zabierzów,
Poland), that will be recorded digitally using the data
base software CARDIO TEKA v001 (ASPEL, Zabierzów,
Poland). Respecting the right to privacy of the partici-
pants, the electrocardiogram will be conducted in the
most private manner behind close curtains.
Biological sample collection
Blood sugar will be measured using a blood glucose meter
ACCU-CHEK Aviva (Roche Diagnostic, Indianapolis, IN,
USA) with ACCU-CHEK AVIVA Glucose reactive strips
(Roche Diagnostic, Indianapolis, IN, USA). Total choles-
terol on the blood will be measured only for participants
with more then eight hours fasting, using a point-of-care
device ACCUTREND Plus (Roche Diagnostic, Indianapolis,
IN, USA) with ACCUTREND CHOLESTEROL reactive
strips (Roche Diagnostic, Indianapolis, IN, USA). A urine
sample will be collected for assessment of urinary creatin-
ine and microalbumin using test strips AUTION SCREEN
(Arkray Europe, Amstelveen, The Netherlands). Finger-
prick blood samples will be collected and spotted onto
Whatman™ 3MMChr filter paper (Fisher Scientific,
Pittsburgh, PA, USA). Blood spots on filter paper will
be left to air dry and them stored at 4 °C.
Referral of participants with clinical alterations
All participants with abnormal clinical results will be
referred to the General Hospital of Bengo for a medical
visit. A specific form was designed to follow clinical
characteristics and treatment prescriptions. The adher-
ence to treatment is evaluated according Morisky Medi-
cation Adherence Scale of 4 items [18].
Future study waves
It’s expected to follow-up the cohort every 3 years using
the same protocol, enabling the identification of trends
and associations between risk factors and outcomes.
Using the Verbal Autopsy System of the Dande-HDSS
adapted from the WHO standardized form [19], data
will be crossed and deaths of individuals in this cohort
can be identified and linked. For the follow-up of the
cohort and aiming to minimise losses, the tracking of
participants will be based on the periodic visits to all
households of the study area held in the scope of the
Dande-HDSS.
Quality control
The training of the field workers was conducted until
the required competency was achieved for their specific
tasks, and tested on the pilot study. A senior staff mem-
ber of Dande-HDSS, responsible for the participant’s
enrolment and process trough the survey, will supervise
all the fieldwork. Participants will be taken through the
testing protocol in a sequential method, to prevent loss of
data or stack in a particular station. Raw data from the
field will be supervised every week to ensure the quality of
data collected. Regular feedbacks between the field team
and research assistants are schedule. All equipment will
be maintained, serviced and calibrated according to man-
ufacturer’s specifications and schedules.
Data management
All questionnaires will be coded by experienced trained
personnel and data will be double entered into a Post-
greSQL® database. A series of logic checks will be per-
formed and if any outliers are encounter, discrepancies
will be followed up with research assistants and field su-
pervisors. All digital data will be stored in password-
protected files and hard copies of questionnaires ware-
housed in locked cabinets in the facilities of CISA, in
Angola. Dande-HDSS supervision team will manage the
access to the databases, ensuring the confidentiality of
personal records of the participants. Files were designed
to store all information related to participant identifica-
tion separated from the remaining data collected so that
all procedures, namely analysis, are maintained under
anonymity.
Statistical analysis
Descriptive data will be reported as absolute frequencies
and percentages, means and standard deviations as ap-
propriate. Contingency tables with Pearson chi-squared
tests and pairwise correlations will be used to identify
variables associated with hypertension, hyperglycemia
and hypercholesterolemia. Logistic regression models
will be fitted, adjusting for potential confounding factors.
Crude and adjusted odds ratios should be estimated for
the identified variables with significant association. Ad-
justed prevalence ratios, computed using Poisson regres-
sion models with robust estimator [20], will also be used
when appropriate. During follow-up, incidence rates will
be calculated as the number of new cases divided by the
total person-time at risk. Time at risk will be counted as
the time between 2 evaluations for subjects who remained
free of the index problem, and for the new cases, time at
risk will be assumed as the midpoint of the time interval
between evaluations. 95 % confidence intervals will be
calculated and a significance level of p < 0.05 will be set
for all determinations.
Discussion
The rise in CVDs and other NCDs is a major issue for
global health, particularly in LMI countries, though not
all countries have the resources to build national surveil-
lance systems to provide solid data on the epidemiology
of such diseases. In their absence and of the data from a
nationwide STEPS, monitoring of NCDs can be
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envisaged by structures such as the Dande-HDSS, which
may contribute for the surveillance of the major chronic
NCD risk factors in representative populations [21].
Due to unequal access to health care, periodic
population-based studies based in HDSS can help to
overcome the lack of health information, being use-
ful in detecting variables such as risk factors, aware-
ness rates and prevalence of symptoms, otherwise
difficult to register in a facility-based system [22].
Being in an early stage of an epidemiological transi-
tion, Angola presents at the same time, an increase in
premature deaths cause by NCDs and high rates of
maternal and chid mortality caused by infections dis-
eases [23]. The country stills records one of the highest
rates of maternal mortality in the world (460 deaths per
100,000 live births) [24]. In this sense, the inclusion of a fe-
male reproductive history in this study and the possibility
of cross information with morbidity and mortality data are
an important component for the study of maternal health.
As in any longitudinal study, there will be a risk of
dropout. Such problem is more common in cohort stud-
ies in Sub Saharan countries due to significant migration
patterns and absence of usual means of follow-up used
in high income-countries, such as central electronic
medical records or unique identifiers to link different
datasets [22, 25]. However, as described earlier, we
predict to have periodic visits to all participants to keep
them motivated between surveys, with a strong effort in
all contacts to explain the purpose of the study and
make people feel they are making a contribution. The
engagement of local authorities is a key factor is this
process, helping to build a relationship of trust with the
participants. Also, additional resources and strategies
can be applied to further follow-ups, such as the use of
cell phones to contact and schedule follow-up visits and
use weekend days to collect data.
Considering the settings where the protocol was ap-
plied, often in rural and inhospitable access hamlets,
with straw dwellings and precarious structures, it will be
necessary to create conditions for the application of the
survey, in case of lack of an appropriate local structure
(as a school, a church or a health centre). For this
matter, the team projected and prepared a kind of a tent,
using awnings and screens to ensure the comfort and
privacy of the participants in the study and use it as
study platform.
These harder conditions of the terrain and in the ab-
sence of local facilities to conduct laboratory tests or a
reliable chain of refrigeration to maintain the right stor-
age conditions for venous blood and urine, we choose to
conduct dry chemistry using point of care devices that
insure reliable results. In future follow-up actions, the
possibility to adopt other laboratory methodologies is
under consideration, such as the inclusion of the
determination of the ratio of apolipoprotein B to apoli-
poprotein A-1.
Even using the STEPS methodology for better compar-
isons, due to the methodological differences namely in
sampling frames and age groups used, direct compari-
sons between studies sometimes are not possible. The
majority of the studies regarding CVDs and their risk
factors only include individuals aged above 25 years.
Having this in mind, we decided to maintain individuals
aged 15–24 years in this study, because we want to
create a cohort with a long-term follow-up, detecting
how CVDs risk factors evolve in younger fractions of the
population. If require to better compare results with
other studies the necessary steps will be made to calculate
the adjusted prevalence’s.
In summary, CardioBengo can represent a solid base-
line to launch a cohort able to provide critical data for
the development of meaningful public health policy,
integrated in the Angolan National Plan of Sanitary
Development for the period 2012–2025, that predicts
the need of further knowledge on CVDs in Angola to
guide health promotions initiatives to the right group
and problem [26].
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